PTU - Polskie Towarzystwo Urologiczne
list of articles:

Article published in Urologia Polska 1999/52/2.


Piotr Kaczmarek, Eugeniusz Miękoś, Jerzy Niemirowicz, Waldemar Różański
Klinika Urologii I. CH. WAM w Łodzi
Kierownik Kliniki: prof.dr hab. E. Miękoś
Oddział Urologii Zarządu Służby Zdrowia MSW w Łodzi
Ordynator: dr n. med. Jerzy Niemirowicz


bladder neoplasma immunotherapy


Introduction. Proper methods of superfcial bladder neoplasms treatment
depend among others on both, the degree of bladder wall infiltration and cellular
anaplasia. The treatment of such a disease resolves itself to tumour
electroresection and intrabladder infusions in order to prolong the period of
tumour remission or to counteract neoplasm recurrence.
Aim Assessment of the efectiveness of preparations such as adriblastyna,
epirubicyna and BCG suspension applied in the continuation of superficial
bladder neoplasms treatment.
Material and method. Assessment of the effectiveness ofrespective
preparations was performed in 212 patients allotted into four groups
dependently on the kind of the applied Preparation and the control group with
no Preparation administered. The preparations were applied in the form of
intrabladder instylations.
Results. Significant dependency was found among particular groups of
patients and the control group. However, the highest efficacy was observed in
the group in which BCG suspension was applied.
Conclusions. Application of preparations in the form of intrabladder
instylations significantly prolongs the neoplasm rate remission the most effective
is BCG suspension.


  1. [1] Boccafoshi, C, Montefiore, F., Pavesi, M., Pastormelo, M., Betta, P.:
  2. Late effects ofintravesical BCG immunotherapy on bladder mucosa infiltrating. Eur. Urol.
  3. 1995,27,334-338.
  4. [2] Bowyer, L., Hall, R. R., Reading, ]., Marsh, M.: The persistence of bacille
  5. Calmette-Guerin in the bladder after intravesical treatment for bladder cancer. B. J.
  6. Urol. 1995, 75, 2,188-92.
  7. [3] Fellows, G. J., Parmar, M. K? Grigor, K. M? Hall, R. R., Heal, M.R.,
  8. Wallace, D. M.: Marker tumour response to Evans and Pasteur BCG in multiple
  9. recurrent pTa/pTl bladder tumours. Br. J. Urol. 1994, 73, 6, 639-644.
  10. [4] Kaczmarek, R, Miękoś, E., Kaczmarek, ].: Instylacje dopęcherzowe z zawie-
  11. siny prątka BCG w leczeniu powierzchownych guzów pęcherza moczowego (pgpm).
  12. Urol. Pol. 1995, 3,189-193.
  13. [5] Keampfer, R., Gerez, L., Farbstein, H., Madar, L., Hirschman, O., Nus-
  14. sinovich, R., Shapiro, A.: Prediction of response to treatment in superficial
  15. bladder carcinoma through pattern of interleukin-2 gene expression. J. Clin. On-
  16. col. 1996,1778-1786.
  17. [6] Lamm, D. L., Thor, D. E., Stogdill, V. D., i wsp.: Bladder cancer immuno-
  18. therapy. J. Urol. 1982,128, 931-935.
  19. [7] Mack, D., Frick, J.: Low-dose BCG in superficial cancer with strain Connaught
  20. Canada - as ejfective as strain Pasteur Paris. Eur. J . Cancer 1994, 30 A, 11,1728-
  21. 1729.
  22. [8] Nista, A., Mattioni, M., Gismondi, A., Palmieri, G., Santoni, A.: Beta 1
  23. - intergin expression and function in human bladder cancer cells: Modulation by
  24. TNF alpha. Anticancer Research 1996, 2, 581-588.
  25. [9] Pryor, K., Goddart, J., Goldstein, D., Strickeer, P., Russell, R, Golo-
  26. vski, D., Penny, R.: BCG enhances monocyte and lymphocyte - mediated blad-
  27. der toumor cell killing. Br. J. Cancer 1995, 71, 801-807.
  28. [10] Ribera, M., Bielsa, ]., Mantrrola, J. M., Fernandez, M. T., Ferrandiz,
  29. C: Mycobacterium bovis - BCG infection of the glans penis: a complication of
  30. intravesical administration of BCG. Br. J. Dermatol. 1995,132, 309-310.
  31. [11] Salman, T., Elahmady, O., Elshafee, M., Omar, S., Salman, I.: Cathep-
  32. sin-D and TNF-alpha in bladder cancer. Disease Marcers 1996,4, 253-259.
  33. [12] Sander, B., Damm, O., Gustafsson, B., Andersson, U., Hacansson, L.:
  34. Localization of Il-l, 11-2, 11-4, 11-8 and TNF in superficial bladder tumors treated
  35. with intravesical BCG. J. Urol. 1996,156.
  36. [13] Schellhammer, P. F, Ladaga, L. E, Fillion, M. B.: Bacillus Calmette-Guerin
  37. for superficial transitional cell carcinoma of the bladder. J. Urol. 1986,135, 261-
  38. 264.
  39. [14] Thanhuser, A., Bohle, A., Scheider, B., Relling, N., Mattern, T., Ernst,
  40. M., Flad, H. D., Ulmer, A. J.: The induction of bacillus-Calmette-Guerin-
  41. actwated killer cells reguires the presence of monocytes and t-helper type-1 cells.
  42. Cancer Immunol. Immunother. 1995, 40,103-108.